Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

Core Insights - Priovant Therapeutics announced positive results from the Phase 2 BEACON study for brepocitinib in cutaneous sarcoidosis, marking a significant milestone in the treatment of this neglected disease [1][2] Company Overview - Priovant Therapeutics is focused on developing novel therapies for autoimmune diseases with high morbidity and limited treatment options [10] - The lead asset, brepocitinib, is a dual selective inhibitor of TYK2 and JAK1, targeting key cytokines linked to autoimmunity [10] - The company plans to initiate a Phase 3 program for cutaneous sarcoidosis in 2026, following engagement with the FDA [7][10] Study Details - The BEACON study enrolled 31 patients across 15 sites in the U.S., with a randomized design comparing brepocitinib 45 mg, 15 mg, and placebo over a 16-week treatment period [2][5] - The 45 mg treatment group included patients with longstanding and difficult-to-treat disease, yet achieved significant clinical improvements compared to placebo [2][5] Efficacy Results - Brepocitinib 45 mg achieved a 22.3-point mean improvement in the Cutaneous Sarcoidosis Activity and Morphology Instrument – Activity score (CSAMI-A) at Week 16, compared to a 0.7-point improvement in placebo (Δ 21.6, P<0.0001) [3][5] - 100% of patients in the 45 mg group achieved at least a 10-point improvement on CSAMI-A, while 62% reached functional remission (CSAMI-A <5) [4][5] Patient Outcomes - On the Investigator's Global Assessment (IGA), 69% of brepocitinib 45 mg patients achieved a two-point improvement to "Clear" or "Almost Clear," compared to 0% in the placebo group (Δ 69%, P=.0047) [5][6] - Brepocitinib also showed significant improvements in key patient-reported outcomes, with 100% of 45 mg patients reporting improvement on the Patient's Global Impression of Change (PGI-C) [6] Safety Profile - Brepocitinib was well tolerated, with no serious adverse events reported and all adverse events classified as mild or moderate [7] - The safety profile aligns with that of other approved JAK1 and TYK2 inhibitors, having been evaluated in over 1,500 patients [7]